Inovio partnered with VGX to co-develop and commercialize Inovio's SynCon therapeutic vaccines for HBV and HCV infection

Inovio Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$78.9m on 10/14/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

VGX International Inc.

South Korea / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced